Australian regulators clear Scribe Therapeutics to begin testing a one-time CRISPR therapy designed to lower “bad” cholesterol for years.
Cardiovascular disease remains the world’s biggest killer, yet one of its main drivers – elevated LDL cholesterol – is often treated with therapies people must take for years, sometimes decades. That reality has shaped the cholesterol market for generations: daily pills, repeat injections and the constant challenge of long-term adherence.
Now, California-based biotech company Scribe Therapeutics is putting it out there that a single treatment could eventually change that equation.
The company has secured clearance from Australia’s Therapeutic Goods Administration to begin the first human trial of STX-1150, an experimental CRISPR-based therapy designed to durably reduce LDL cholesterol in people at increased cardiovascular risk [1]. Rather than permanently editing DNA, STX-1150 works by “silencing” a gene called PCSK9 in the liver, effectively turning down one of the body’s mechanisms for maintaining high cholesterol levels. The aim is long-lasting cholesterol reduction after just one dose.
For longevity investors and researchers, the significance extends beyond cholesterol itself. We are moving from treating disease after damage occurs to intervening earlier, with therapies designed to reduce risk over the long term.
Cholesterol remains a massive longevity problem
Despite decades of innovation in cardiovascular medicine, heart disease continues to dominate mortality statistics globally. In the US alone, more than 120 million people are affected by cardiovascular disease, and someone experiences a heart attack roughly every 40 seconds.
Statins and newer cholesterol-lowering drugs have helped millions of patients. However, in real-world settings, many people still fail to reach recommended LDL targets. Some stop treatment because of side effects, others struggle with the burden of chronic medication, while many simply begin treatment too late, after years of silent arterial damage have already accumulated. That gap between clinical potential and real-world behavior is increasingly becoming a target for next-generation biotech companies.
Scribe’s approach attempts to solve a practical problem as much as a scientific one: if patients struggle to maintain lifelong treatment, could medicine instead deliver durable protection upfront?
“Advancing STX-1150 into the clinic marks a pivotal moment for Scribe,” said Dr Benjamin Oakes, co-founder and CEO of Scribe Therapeutics. “Years of iterative engineering to enhance the potency and specificity of our CRISPR technologies [have] culminated in our first clinical program designed to provide access to the effects of known cardioprotective genetics, potentially freeing patients from decades of treatment burden.”
‘Not permanent editing’
CRISPR therapies are often associated with permanent gene editing, a prospect that still raises regulatory and ethical questions. Scribe is positioning STX-1150 differently. The therapy uses what the company calls an “epigenetic silencing” approach. In simpler terms, it is designed to suppress the activity of the PCSK9 gene without permanently rewriting the DNA itself. That distinction could prove commercially and clinically important.
The company says its ELXR platform is intended to deliver long-lasting effects while maintaining reversibility, potentially giving physicians a middle ground between conventional drugs that require constant dosing and irreversible gene editing approaches.
The science builds on years of evidence surrounding PCSK9, one of the most validated cholesterol targets in modern medicine. People born with naturally low-functioning versions of the gene tend to have substantially lower LDL cholesterol levels and dramatically reduced rates of coronary heart disease throughout life.
Scribe’s therapy aims to recreate part of that protective effect therapeutically.
The first human test begins in Australia and New Zealand
The Phase 1 study will enroll up to 64 adults with elevated LDL cholesterol who are considered at increased cardiovascular risk. Participants will receive escalating doses of the therapy and be monitored for one year.
The first clinical site will open at Monash Health’s Victorian Heart Hospital in Australia, with renowned cardiologist Dr Stephen Nicholls leading the study.
“The initiation of Scribe’s first-in-human study reflects a critical advance in the development of much-needed, highly durable approaches to LDL-C reduction,” said Nicholls. “Targeting PCSK9 with an innovative epigenetic silencing strategy, STX-1150 offers a differentiated approach to long-term lipid management.”
For investors watching the longevity space, the trial represents more than another CRISPR milestone. It signals how the field is increasingly converging around prevention, durability and scalability – three themes rapidly becoming central to healthy lifespan extension.
Much of longevity medicine has historically focused on supplements, diagnostics or lifestyle optimization, but therapies like STX-1150 suggest a future where preventive genetic medicines may eventually target the chronic diseases most responsible for aging-related decline.
Whether Scribe’s approach succeeds clinically remains to be seen. Nonetheless, the company’s move into human trials underscores how longevity is no longer only about extending lifespan at the margins; it is increasingly about intercepting disease decades earlier, before the damage compounds.
